The canada pharmaceutical market size was valued at USD 42.01 billion in 2025 and is estimated to grow from USD 43.55 billion in 2026 to reach USD 55.29 billion by 2031, at a CAGR of 4.89% during the forecast period (2026-2031). This report is Segmented by Product Type (Prescription Drugs [Patented, Generics], OTC), Therapeutic Class (Antineoplastics & Immunomodulators, Alimentary Tract & Metabolism, and More), Route of Administration (Oral, Parenteral, Topical, Inhalation, Others), Distribution Channel (Retail, Hospital, and More), Payer Type (Public, and More), and Geography. Market Forecasts are Provided in Value (USD).
Over-the-counter medicines posted a modest CAGR as supermarket consolidation and private-label competition eroded branded demand. Health Canada’s breakthrough pathway now halves median review times for life-threatening conditions, yet provincial reimbursement negotiations still extend the journey to bedside by up to a year. Ontario caps most generic prices at 25% of the corresponding brand, squeezing margins but sustaining widespread access. Removal of codeine-containing analgesics from OTC shelves in 2024 shifted an estimated CAD 180 million (USD 133 million) in sales to prescription settings.
Antineoplastics and immunomodulators controlled 26.34% of therapeutic spending in 2025, underscoring continued investment in targeted and cell-based oncology treatments. Anti-infectives are projected to rise at 7.02% CAGR to 2031, buoyed by stockpiling programs and rising antimicrobial-resistance rates. Drugs for the alimentary tract and metabolism held 18.2% share, bolstered by strong demand for SGLT2 and GLP-1 agents. Nervous-system medications accounted for 15.7%, while cardiovascular drugs contributed 12.4% as PCSK9 inhibitors countered generic statin erosion. Health Canada cleared 14 novel anti-infectives in 2024, and reserve antibiotics such as cefiderocol have become integral to hospital protocols. Oncology spending per capita reached CAD 412 (USD 305) in 2025, although confidential rebates reduce net impact on budgets.
Canada Pharmaceutical Market Trends and Insights
Rising Chronic-Disease Prevalence & Aging Population
Canada counted 7.3 million residents aged 65 and older in 2024, equal to 18.5% of the population, and that cohort is expected to top 9.5 million by 2030.Chronic illnesses already absorb around 67% of direct health-care costs, led by cardiovascular disease and type 2 diabetes. Multimorbidity reached 29% among adults aged 45-64 in 2025, driving provincial plans to integrate pharmaceutical and non-pharmaceutical care pathways. Pharmaceutical firms have responded with fixed-dose combinations and long-acting injectables that simplify regimens, while payers negotiate outcomes-based contracts tied to hospital-admission reductions. Updated 2024 cardiovascular guidelines that favor SGLT2 and GLP-1 agents widened eligible populations and further stimulated demand.Surge in Specialty Biologics & Orphan Drugs
Health Canada granted 42 Notices of Compliance for biologic therapies in 2024, a 23% jump over 2023. Oncology and immunology indications dominated approvals, and orphan-drug designations multiplied after criteria were harmonized with U.S. frameworks. Provincial funding for CAR-T cell therapies in Ontario and Quebec began in 2025, albeit only at certified centers that can manage apheresis and cytokine-release monitoring. List prices for emerging gene therapies regularly exceed CAD 2 million (USD 1.5 million), triggering installment payment models that tie final disbursements to clinical outcomes. Although high, these prices still fit budget envelopes once offset by avoided lifetime treatment costs and hospitalizations.PMPRB Price-Control Reforms Heighten Launch Risk
Revised 2024 guidelines removed the United States and Switzerland from the reference basket and introduced pharmacoeconomic ceilings, cutting median list prices by 22% and delaying oncology listings by nine months. Eighteen products exceeded caps in 2025, triggering CAD 47 million (USD 35 million) in claw-backs. Several multinationals now launch first in markets with faster reimbursement, narrowing early access for Canadian patients.Other drivers and restraints analyzed in the detailed report include:
- Provincial Biosimilar Switching Policies Unlock Savings
- Expansion of Early-Phase Clinical Trials in Canada
- Heavy Reliance on Imports Exposes Supply-Chain Fragility
Segment Analysis
Prescription drugs captured 44.24% of 2025 sales, and the segment is set to grow at 6.82% through 2031. Patented therapies controlled 62% of prescription revenue, propelled by checkpoint inhibitors, GLP-1 agonists, and gene therapies. Generics represented 38% of revenue yet 78% of total units dispensed, reflecting sustained price erosion from competitive tenders.Over-the-counter medicines posted a modest CAGR as supermarket consolidation and private-label competition eroded branded demand. Health Canada’s breakthrough pathway now halves median review times for life-threatening conditions, yet provincial reimbursement negotiations still extend the journey to bedside by up to a year. Ontario caps most generic prices at 25% of the corresponding brand, squeezing margins but sustaining widespread access. Removal of codeine-containing analgesics from OTC shelves in 2024 shifted an estimated CAD 180 million (USD 133 million) in sales to prescription settings.
Antineoplastics and immunomodulators controlled 26.34% of therapeutic spending in 2025, underscoring continued investment in targeted and cell-based oncology treatments. Anti-infectives are projected to rise at 7.02% CAGR to 2031, buoyed by stockpiling programs and rising antimicrobial-resistance rates. Drugs for the alimentary tract and metabolism held 18.2% share, bolstered by strong demand for SGLT2 and GLP-1 agents. Nervous-system medications accounted for 15.7%, while cardiovascular drugs contributed 12.4% as PCSK9 inhibitors countered generic statin erosion. Health Canada cleared 14 novel anti-infectives in 2024, and reserve antibiotics such as cefiderocol have become integral to hospital protocols. Oncology spending per capita reached CAD 412 (USD 305) in 2025, although confidential rebates reduce net impact on budgets.
Complete Report Scope:
- By Product Type
- Prescription Drugs
- Patented
- Generics
- OTC
- Prescription Drugs
- By Therapeutic Class
- Antineoplastics & Immunomodulators
- Alimentary Tract & Metabolism
- Nervous System
- Cardiovascular
- Respiratory
- Anti-infectives
- Blood & Blood-forming
- Sensory Organs
- Others
- By Route of Administration
- Oral
- Parenteral
- Topical
- Inhalation
- Others
- By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Mail-Order / Online Pharmacies
- Specialty Pharmacies
- Wholesalers & Distributors
- By Payer Type
- Public Drug Plans
- Private Insurance
- Out-of-Pocket
List of Companies Covered in this Report:
- Abbvie
- Amgen
- Apotex
- AstraZeneca
- Bausch Health
- Bayer
- Boehringer Ingelheim
- Eli Lilly and Company
- Roche
- GlaxoSmithKline (GSK)
- Johnson & Johnson
- Merck
- Novartis
- Novo Nordisk
- Paladin Labs
- Pfizer
- Sandoz Group
- Sanofi
- Takeda Pharmaceuticals
- Teva Pharmaceuctials Ltd
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value in USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Amgen
- Apotex
- AstraZeneca
- Bausch Health
- Bayer
- Boehringer Ingelheim
- Eli Lilly
- F. Hoffmann La Roche Ltd
- GlaxoSmithKline (GSK)
- Johnson & Johnson (Janssen)
- Merck
- Novartis
- Novo Nordisk
- Paladin Labs
- Pfizer
- Sandoz
- Sanofi
- Takeda
- Teva Pharmaceuctials Ltd
